12th annual Sesame Workshop Benefit Gala in New York City. (Photo by Robin Marchant/Getty Images)
Sesame Street recently launched a venture investment arm working with early stage investment firm Collaborative Fund. Children’s health is one area of interest for Sesame Ventures, along with startups developing technology focused on education. In its first announced healthcare collaboration, Sesame Ventures will have a judge participate in the Impact Pediatric Health Pitch event at SXSW Interactive next month, according to a press statement.
Will Fowler, vice president of strategic planning for Sesame Workshop, will be part of a panel of judges for the event.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
He’ll join a group representing Children’s Hospitals including:
- Dr. Kevin Maher, the director of Cardiac Intensive Care and co-director of the Center for Pediatric Innovation, Children’s Healthcare of Atlanta;
- Jessica Rousset, director of the Center for Innovation, Children’s Hospital Los Angeles;
- Dr. Wendy Sue Swanson, executive director of digital health at Seattle Children’s Hospital; and
- Dr. James Wall, assistant professor of Pediatric Surgery and Bioengineering at Stanford Children Health/Lucile Packard Children’s Hospital Stanford
Among the criteria for the event are technologies that fall into these areas:
- Patient safety, population health and management, prematurity, remote care, or hospital to home transitions;
- Precision Medicine, specifically genomics; and
- Med Tech, specifically robotics or minimally invasive surgery, 3D printing or artificial intelligence.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The deadline for applications to pitch has been extended to February 15.
